News >

Ipilimumab Approved in Europe for Pediatric Melanoma

Jason Harris
Published: Monday, Jan 22, 2018

Peter Mohr, MD

Peter Mohr, MD
Ipilimumab (Yervoy) has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.

Ipilimumab is approved in more than 50 countries for the treatment of patients with unresectable or metastatic melanoma.
European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma. Bristol-Myers Squibb. Published online and accessed January 22, 2018. http://bit.ly/2DVq5K5.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x